Insulet Co. (NASDAQ:PODD) Receives $272.81 Average Target Price from Analysts

Insulet Co. (NASDAQ:PODD) has been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $272.81.

PODD has been the topic of a number of recent analyst reports. Citigroup increased their price target on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group increased their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Wells Fargo & Company upped their price target on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Finally, TD Cowen raised their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd.

Insulet Trading Down 1.0 %

Insulet stock opened at $264.38 on Monday. The firm has a market cap of $18.54 billion, a PE ratio of 45.27, a P/E/G ratio of 4.12 and a beta of 1.22. Insulet has a 12 month low of $160.19 and a 12 month high of $279.77. The stock’s 50 day simple moving average is $265.09 and its two-hundred day simple moving average is $231.39. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Blue Trust Inc. increased its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares in the last quarter. Friedenthal Financial acquired a new stake in shares of Insulet in the 4th quarter worth $57,000. TD Private Client Wealth LLC raised its holdings in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the period. Finally, Versant Capital Management Inc raised its holdings in shares of Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after acquiring an additional 157 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.